Isoquinolinesulphonamide derivatives inhibit transcriptional elongation of human immunodeficiency virus type 1 RNA in a promyelocytic model of latency

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 5, 1999, Pages 275-284

  Critchfield, J W ^a   Ho, O ^a   Roberts, B D ^a   Van Lint, C ^b   Verdin, E ^c   Butera, S T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cellular factors; HIV 1 latency; Transcriptional inhibitors

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ISOQUINOLINE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; SULFONAMIDE; VIRUS RNA;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MODEL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; VIRUS LATENCY; VIRUS TRANSCRIPTION;

EID: 0032843282     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000506     Document Type: Article

References (48)

1. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, Groudine M & Emerman M (1994) Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proceedings of the National Academy of Sciences, USA 91:3862-3866.
2. Antoni BA, Rabson AB, Kinter A, Bodkin M & Poli G (1994) NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology 202:684-694.
3. Baba M (1997) Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Research 33:141-152.
4. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T & Okamoto T (1998) Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquincline derivatives. Molecular Pharmacology 53:1097-1103.
5. Beg AA, Finco TS, Nantermet PV & Baldwin AS Jr (1993) Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IKBα: a mechanism for NF-κB activation. Molecular and Cellular Biology 13:3301-3310.
6. Biswas DK, Ahlers CM, Dezube BJ & Pardee AB (1994) Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NF-kappa B induced gene expression. Molecular Medicine 1:31-43.
7. Butera ST & Folks TM (1992) Application of latent HIV-1 infected cellular models to therapeutic intervention. AIDS Research and Human Retroviruses 8:991-995.
8. + model of chronic infection. Journal of Virology 65:4645-4653.
9. + model of chronic infection. Journal of Immunology 150:625-634.
10. Butera ST, Roberts BD, Lam L, Hodge T & Folks TM (1994) Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. Journal of Virology 68:2726-2730.
11. Butera ST, Roberts BD, Critchfield JW, Fang G, McQuade T, Gracheck SJ & Folks TM (1995) Compounds that target novel cellular components involved in HIV-1 transcription. Molecular Medicine 1:758-767.
12. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA & Fauci AS (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences, USA 94:13193-13197.
13. + T cells using a combination of cytokines. Journal of Experimental Medicine 188:83-91.
14. Cohen PS, Schmidtmayerova H, Dennis J, Dubrovsky L, Sherry B, Wang H, Bukrinsky M & Tracey KJ (1997) The critical role of p38 MAP kinase in T cell HIV-1 replication. Molecular Medicine 3:339-346.
15. Critchfield JW, Butera ST & Folks TM (1996) Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Research and Human Retroviruses 12:39-46.
16. Critchfield JW, Coligan JE, Folks TM & Butera ST (1997) Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proceedings of the National Academy of Sciences, USA 94:6110-6115.
17. Duh EJ, Maury WJ, Folks TM, Fauci AS & Rabson AB (1989) Tumor necrosis factor-alpha activates human immunodeficiency virus-1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proceedings of the National Academy of Sciences, USA 86:5974-5978.
18. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K & Haase AT (1993) Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-362.
19. Feorino PM, Butera ST, Folks TM & Schinazi RF (1993) Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells. Antiviral Chemistry & Chemotherapy 4:55-63.
20. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD & Siliciano RF (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
21. Finzi D & Siliciano RF (1998) Viral dynamics in HIV-1 infection. Cell 93:665-671.
22. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS & Wolinsky SM (1999) Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New England Journal of Medicine 340:1614-1622.
23. Griffin GE, Leung K, Folks TM, Kunkel S & Nabel GJ (1989) Activation of HIV gene expression during monocytic differentiation by induction of NF-κB. Nature 339:70-73.
24. Herrmann CH, Carroll RG, Wei P, Jones KA & Rice AP (1998) Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. Journal of Virology 72:9881-9888.
25. Hidaka H, Inagaki M, Kawamoto S & Sasaki Y (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23:5036-5041.
26. Kinter AL, Poli G, Maury W, Folks TM & Fauci AS (1990) Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. Journal of Virology 64:4306-4312.
27. Kopp E & Ghosh S (1994) Inhibition of NF-κB by sodium salicylate and aspirin. Science 265:956-959.
28. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS & Pardee AB (1993) Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proceedings of the National Academy of Sciences, USA 90:1839-1842.
29. Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, Zhu Y, Peng J, Blau C, Hazuda D, Price D & Flores O (1997) P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes and Development 11:2633-2644.
30. Mihm S, Ennen J, Pessara U, Kurth R & Droge W (1991) Inhibition of HIV-1 replication and NF-κB activity by cysteine and cysteine derivatives. AIDS 5:497-503.
31. Osborn L, Kunkel S & Nabel GJ (1989) Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proceedings of the National Academy of Sciences, USA 86:2336-2340.
32. Pazin MJ, Sheridan PL, Cannon K, Cao Z, Keck JG, Kadonaga JT & Jones KA (1996) NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes and Development 10:37-49.
33. Qatsha KA, Rudolph C, Marme D, Schachtele C & May WS (1993) Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proceedings of the National Academy of Sciences, USA 90:4674-4678.
34. Quick J, Ware JA & Driedger PE (1992) The structure and biological activities of the widely used protein kinase inhibitor, H-7, differ depending on the commercial source. Biochemical and Biophysical Research Communications 187:657-663.
35. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA & Herzenberg LA (1990) Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proceedings of the National Academy of Sciences, USA 87:4884-4888.
36. Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K & Kronke M (1992) TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 71:765-776
37. Seshamma T, Bagasra O, Trono D, Baltimore D & Pomerantz RJ (1992) Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 89:10663-10667.
38. Sheridan PL, Sheline CT, Cannon K, Voz ML, Pazin MJ, Kadonaga JT & Jones KA (1995) Activation of the HIV-1 enhancer by the LEF-1 HMG protein on nucleosome-assembled DNA in vitro. Genes and Development 9:2090-2104.
39. Sun S-C, Ganchi A, Ballard DW & Green WC (1993) NF-κB controls expression of inhibitor IκBα: evidence for an inducible autoregulatory pathway. Science 259:1912-1915.
40. Takagi A, Yamada Mizutani M, Tomioka N & Itai A (1996) Inhibition mechanisms of staurosporine and H7 to cAMP-dependent protein kinase through docking study. Chemical & Pharmaceutical Bulletin 44:618-620.
41. Turpin JA, Buckheit RW Jr, Derse D, Hollingshead M, Williamson K, Palamone C, Osterling MC, Hill SA, Graham L, Schaeffer CA, Bu M, Huang M, Cholody WM, Michejda CJ & Rice WG (1998) Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrobial Agents and Chemotherapy 42:487-494.
42. Van Lint C, Emiliani S, Ott M & Verdin E (1996a) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO Journal 15:1112-1120.
43. Van Lint C, Emiliani S & Verdin E (1996b) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expression 5:245-253.
44. Verdin E, Paras P Jr & Van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO Journal 12:3249-3259.
45. Wei P, Garber ME, Fang SM, Fischer WH & Jones KA (1998) A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462.
46. Wiegmann K, Schutze S, Kampen E, Himmler A, Machleidt T & Kronke M (1992) Human 55 kD receptor for tumor necrosis factor coupled to signal transduction cascades. Journal of Biological Chemistry 267:17997-18001.
47. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ & Martin MA (1988) In vitro mutagensis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. Journal of Virology 62:139-147
48. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA & Richman DD (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.